摘要
目的克赛(依诺肝素)治疗不稳定型心绞痛(UA)的效果和安全性。方法将UA患者随机分为两组,治疗组65例,对照组64例,治疗组用克赛1次/12小时,共7天;对照组用安慰剂,1次/12小时,共7天。结果治疗组疗效明显优于对照组,治疗组显效率86.3%,总有效率95.4%;对照组的显效率60.9%,总有效率87.5%,两组疗效差异有统计学意义(P<0.05)。结论治疗组比对照组起效快、作用强、效果好、安全性可靠。
Objective To investigate the efficacy and safety of clexane （enoxaparin） in the treatment of unstable angina （UA）. Methods The UA patients were divided into two groups randomly： 65 cases in the treatment group and 64 cases in the control group. The patients in the treatment group were treated with clexane once every 12 hours for a week. The patients in the control group got placebo once every 12 hours for a week. Results Therapeutic outcome of the treatment group was obviously better than that of the control group with the efficiency rate 86.3% vs. 60.9%, total efficiency rate 95.4% vs. 87.5%, with statistically significant difference （P 〈0.05） between the two groups. Conclusions Clexane has quicker, stronger and better effect with more reliable safety in the treatment of unstable angina.
出处
《临床医学工程》
2012年第8期1321-1322,共2页
Clinical Medicine & Engineering
关键词
克赛
UA
疗效
安全
Clexane
Unstable angina
Therapeutic outcome
Safety
